



Cornerstone Pharmaceuticals, Inc
1 Duncan Drive
Cranbury, NJ 08512

Media Contact: Meghan Weber
Liza Sullivan & Associates
(917) 399-8713

Cornerstone Pharmaceuticals Announces \$6 Million Financing to Further Advance Clinical Trials in Cancer Patients

Cranbury, NJ, May 27, 2009 – Cornerstone Pharmaceuticals, Inc., a privately-held pharmaceutical company focused on developing drugs in the emerging field of cancer bioenergetics, announced today that it has raised a minimum of \$6 million from a private investor group. The proceeds are to be primarily used for advancing its clinical trials in the US and Canada evaluating the safety and efficacy of its first-in-class bioenergetic Altered Energy Metabolism-Directed (AEMD) compound, CPI-613, in a variety of cancer types. CPI-613 targets distinctive changes in energy metabolism that are associated with the vast majority of solid tumor types, as observed in non-clinical studies. CPI-613 has shown potential utility in multiple non-clinical studies including those conducted using human tumor biopsies from patients bearing lung, colon, pancreatic and breast tumors as well as cancer cell lines resistant to traditional chemotherapeutics. CPI-613 is the lead product candidate from Cornerstone's AEMD compound platform currently being studied in human clinical trials.

“Raising funds in a challenging market is a strong validation of the potential value of the bioenergetic approach to targeting cancer, and of Cornerstone's novel product candidates for cancer therapy,” said Cliff Straub, Vice President and Chief Financial Officer. The Company's AEMD platform is based upon research conducted by Drs. Bingham and Zachar who are both Cornerstone scientists and faculty members at Stony Brook University. Drs. Bingham and Zachar were recently honored with the Dr. Michael Maffetone Research Award in recognition of their important discoveries in the cancer field at this year's Carol M. Baldwin Breast Cancer Research Fund's gala.

About Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals, Inc. is a privately held company that is committed to changing the way cancer is treated through the discovery and development of innovative therapies capitalizing on the unique metabolic processes of cancer cells. The company's founding members, management and scientific advisory team include pre-eminent scientists focused on cancer cell metabolism, cancer research and drug development. Cornerstone is the only company that currently has a drug in clinical trials targeting certain key enzymes crucial to cancer cell metabolism. The company's unique approach to targeting cancer metabolism has led to the discovery of first-in-class drugs with the potential to transform the way cancer is treated. Its lead drug, CPI-613, is currently being evaluated in three ongoing Phase I and Phase I/II clinical trials in a variety of tumor types. For further information, visit <http://www.cornerstonepharma.com> or contact: Meghan Weber at (917) 399-8713.



#

This release contains forward-looking statements. These statements relate to future events or each company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forwardlooking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.